Search

Your search keyword '"Michael D. Miller"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Michael D. Miller" Remove constraint Author: "Michael D. Miller" Journal antiviral therapy Remove constraint Journal: antiviral therapy
23 results on '"Michael D. Miller"'

Search Results

1. Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir

2. Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor

3. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6

4. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate

5. Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks

6. Trends in HIV-1 Reverse Transcriptase Resistance-Associated Mutations and Antiretroviral Prescription Data from 2003–2010

7. Mutations in the thumb–connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients

8. Prevalence, Genotypic Associations and Phenotypic Characterization of K65R, L74V and other HIV-1 RT Resistance Mutations in a Commercial Database

9. In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents

10. The K65R Reverse Transcriptase Mutation in HIV-1 Reverses the Excision Phenotype of Zidovudine Resistance Mutations

11. Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV

12. Lack of a Metabolic and Antiviral Drug Interaction between Tenofovir, Abacavir and Lamivudine

13. In VitroEvaluation of the Anti-HIV Activity and Metabolic Interactions of Tenofovir and Emtricitabine

14. In VitroCombination Studies of Tenofovir and Other Nucleoside Analogues with Ribavirin against HIV-1

15. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients

16. Increased Drug Susceptibility of HIV-1 Reverse Transcriptase Mutants Containing M184V and Zidovudine-Associated Mutations: Analysis of Enzyme Processivity, Chain-Terminator Removal and Viral Replication

17. In vitroSelection and Characterization of HIV-1 with Reduced Susceptibility to PMPA

18. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients

19. Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools

20. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database

21. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine

22. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine

23. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1

Catalog

Books, media, physical & digital resources